🚀 VC round data is live in beta, check it out!
Supernus Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Supernus Pharmaceuticals and similar public comparables like PegBio, Viridian Therapeutics, InnoCare Pharma, Camurus and more.
Supernus Pharmaceuticals Overview
About Supernus Pharmaceuticals
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Founded
2005
HQ
Employees
674
Website
Sectors
Financials (LTM)
EV
$3B
Supernus Pharmaceuticals Financials
Supernus Pharmaceuticals reported last 12-month revenue of $751M and EBITDA of $158M.
In the same LTM period, Supernus Pharmaceuticals generated $670M in gross profit, $158M in EBITDA, and $172M in net income.
Revenue (LTM)
Supernus Pharmaceuticals P&L
In the most recent fiscal year, Supernus Pharmaceuticals reported revenue of $719M and EBITDA of $157M.
Supernus Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $751M | XXX | $719M | XXX | XXX | XXX |
| Gross Profit | $670M | XXX | $644M | XXX | XXX | XXX |
| Gross Margin | 89% | XXX | 90% | XXX | XXX | XXX |
| EBITDA | $158M | XXX | $157M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 22% | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $172M | XXX | $182M | XXX | XXX | XXX |
| Net Margin | 23% | XXX | 25% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Supernus Pharmaceuticals Stock Performance
Supernus Pharmaceuticals has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Supernus Pharmaceuticals' stock price is $54.33.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | 0.0% | XXX | XXX | XXX | $3.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSupernus Pharmaceuticals Valuation Multiples
Supernus Pharmaceuticals trades at 3.8x EV/Revenue multiple, and 18.0x EV/EBITDA.
EV / Revenue (LTM)
Supernus Pharmaceuticals Financial Valuation Multiples
As of March 21, 2026, Supernus Pharmaceuticals has market cap of $3B and EV of $3B.
Equity research analysts estimate Supernus Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Supernus Pharmaceuticals has a P/E ratio of 18.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | 18.0x | XXX | 18.1x | XXX | XXX | XXX |
| EV/EBIT | 18.0x | XXX | 17.9x | XXX | XXX | XXX |
| EV/Gross Profit | 4.2x | XXX | 4.4x | XXX | XXX | XXX |
| P/E | 18.1x | XXX | 17.2x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 61.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Supernus Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Supernus Pharmaceuticals Margins & Growth Rates
Supernus Pharmaceuticals' revenue in the last 12 month grew by 20%.
Supernus Pharmaceuticals' revenue per employee in the last FY averaged $1.1M.
Supernus Pharmaceuticals' rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Supernus Pharmaceuticals' rule of X is 71% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Supernus Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 71% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 40% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 27% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 15% | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 95% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Supernus Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| PegBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Viridian Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| InnoCare Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Camurus | XXX | XXX | XXX | XXX | XXX | XXX |
| Apeloa Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Supernus Pharmaceuticals M&A Activity
Supernus Pharmaceuticals acquired XXX companies to date.
Last acquisition by Supernus Pharmaceuticals was on XXXXXXXX, XXXXX. Supernus Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Supernus Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSupernus Pharmaceuticals Investment Activity
Supernus Pharmaceuticals invested in XXX companies to date.
Supernus Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Supernus Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Supernus Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Supernus Pharmaceuticals
| When was Supernus Pharmaceuticals founded? | Supernus Pharmaceuticals was founded in 2005. |
| Where is Supernus Pharmaceuticals headquartered? | Supernus Pharmaceuticals is headquartered in United States. |
| How many employees does Supernus Pharmaceuticals have? | As of today, Supernus Pharmaceuticals has over 674 employees. |
| Who is the CEO of Supernus Pharmaceuticals? | Supernus Pharmaceuticals' CEO is Jack A. Khattar. |
| Is Supernus Pharmaceuticals publicly listed? | Yes, Supernus Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Supernus Pharmaceuticals? | Supernus Pharmaceuticals trades under SUPN ticker. |
| When did Supernus Pharmaceuticals go public? | Supernus Pharmaceuticals went public in 2012. |
| Who are competitors of Supernus Pharmaceuticals? | Supernus Pharmaceuticals main competitors are PegBio, Viridian Therapeutics, InnoCare Pharma, Camurus. |
| What is the current market cap of Supernus Pharmaceuticals? | Supernus Pharmaceuticals' current market cap is $3B. |
| What is the current revenue of Supernus Pharmaceuticals? | Supernus Pharmaceuticals' last 12 months revenue is $751M. |
| What is the current revenue growth of Supernus Pharmaceuticals? | Supernus Pharmaceuticals revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Supernus Pharmaceuticals? | Current revenue multiple of Supernus Pharmaceuticals is 3.8x. |
| Is Supernus Pharmaceuticals profitable? | Yes, Supernus Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Supernus Pharmaceuticals? | Supernus Pharmaceuticals' last 12 months EBITDA is $158M. |
| What is Supernus Pharmaceuticals' EBITDA margin? | Supernus Pharmaceuticals' last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Supernus Pharmaceuticals? | Current EBITDA multiple of Supernus Pharmaceuticals is 18.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.